164
Participants
Start Date
Not specified
Study Completion Date
October 31, 1998
Thalidomide
Beth Israel Med Ctr, New York
Bellevue Hosp / New York Univ Med Ctr, New York
Mount Sinai Med Ctr / Pediatrics, New York
Mount Sinai Med Ctr, New York
Bronx Municipal Hosp Ctr/Jacobi Med Ctr, The Bronx
Comprehensive Health Care Ctr / Bronx Municipal Hosp, The Bronx
Montefiore Adolescent AIDS Prog / Bronx Municipal Hosp, The Bronx
Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, The Bronx
Montefiore Family Health Ctr / Bronx Municipal Hosp, The Bronx
Jack Weiler Hosp / Bronx Municipal Hosp, The Bronx
Montefiore Med Ctr / Bronx Municipal Hosp, The Bronx
North Central Bronx Hosp / Bronx Municipal Hosp, The Bronx
Bronx Veterans Administration / Mount Sinai Hosp, The Bronx
SUNY / State Univ of New York, Syracuse
SUNY / Erie County Med Ctr at Buffalo, Buffalo
Howard Univ, Washington D.C.
Univ of Alabama at Birmingham, Birmingham
Meharry Med College, Nashville
Case Western Reserve Univ, Cleveland
Northwestern Univ Med School, Chicago
Cook County Hosp, Chicago
Rush Presbyterian - Saint Luke's Med Ctr, Chicago
Louis A Weiss Memorial Hosp, Chicago
Univ of Colorado Health Sciences Ctr, Denver
Harbor UCLA Med Ctr, Torrance
Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco
Queens Med Ctr, Honolulu
Univ of Hawaii, Honolulu
Milton S Hershey Med Ctr, Hershey
Thomas Jefferson Univ Hosp, Philadelphia
Univ of North Carolina, Chapel Hill
Univ of Miami School of Medicine, Miami
Indiana Univ Hosp, Indianapolis
Illinois Masonic Med Ctr, Chicago
Univ of Southern California / LA County USC Med Ctr, Los Angeles
San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco
Univ of Washington, Seattle
Harvard (Massachusetts Gen Hosp), Boston
Beth Israel Deaconess - West Campus, Boston
Univ of Puerto Rico, San Juan
Collaborators (1)
Andrulis Pharmaceuticals
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH